Modeling Mutual Exclusivity of Cancer Mutations

PLoS Computational Biology

Volumn 10, Issue 3, 2014, Pages

  Szczurek, Ewa ^a,b   Beerenwinkel, Niko ^a,b  

^a ETH ZURICH   (Switzerland)

^b SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; STATISTICAL TESTS; TUMORS;

CANCER GENOMICS; COMPUTATIONAL APPROACH; EXCLUSIVE PATTERNS; GENE SETS; GENOMIC DATA; MUTUAL EXCLUSIVITIES; NUMBER OF SAMPLES; PATTERN COVER; TEST CANDIDATES; TUMOR SAMPLES;

GENES;

ARTICLE; CANCER GENETICS; DATA PROCESSING; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENOMICS; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MUTUAL EXCLUSIVITY MODEL; ONCOGENE; PRECANCER; RPL5 GENE; SIMULATION; STATISTICAL MODEL; SYSTEM ANALYSIS; TRAT1 GENE;

ALGORITHMS; BRAIN NEOPLASMS; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DATABASES, GENETIC; FALSE POSITIVE REACTIONS; GENOME, HUMAN; GENOMICS; GLIOBLASTOMA; HUMANS; MODELS, STATISTICAL; MUTATION; PROBABILITY;

EID: 84897386130     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003503     Document Type: Article

References (26)

1. TCGA (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
2. Garraway LA, Lander ES, (2013) Lessons from the Cancer Genome. Cell 153: 17-37.
3. Miller C, Settle S, Sulman E, Aldape K, Milosavljevic A, (2011) Discovering functional modules by identifying recurrent and mutually exclusive mutational patterns in tumors. BMC Medical Genomics 4: 34+.
4. Vandin F, Upfal E, Raphael BJ, (2012) De Novo discovery of mutated driver pathways in cancer. Genome Res 22: 375-385.
5. Zhao J, Zhang S, Wu LY, Zhang XS, (2012) Efficient methods for identifying mutated driver pathways in cancer. Bioinformatics 28: 2940-2947.
6. Ciriello G, Cerami E, Sander C, Schultz N, (2012) Mutual exclusivity analysis identifies oncogenic network modules. Genome research 22: 398-406.
7. Leiserson MDM, Blokh D, Sharan R, Raphael BJ, (2013) Simultaneous Identification of Multiple Driver Pathways in Cancer. PLoS Comput Biol 9: e1003054+.
8. Yeang CH, Mccormick F, Levine A, (2008) Combinatorial patterns of somatic gene mutations in cancer. FASEB J 22: 2605-2622.
9. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW, (1998) Mutational analysis of the APC/betacatenin/Tcf pathway in colorectal cancer. Cancer Res 58: 1130-1134.
10. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, et al. (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418: 934.
11. Masica DL, Karchin R, (2011) Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival. Cancer Research 71: 4550-4561.
12. Szczurek E, Misra N, Vingron M, (2013) Synthetic sickness or lethality points at candidate combination therapy targets in glioblastoma. International Journal of Cancer 133: 2123-2132.
13. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, et al. (2013) Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotech 31: 213-219.
14. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, et al. (2013) The Somatic Genomic Landscape of Glioblastoma. Cell 155: 462-477.
15. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, et al. (2013) Emerging landscape of oncogenic signatures across human cancers. Nat Genet 45: 1127-1133.
16. Vuong QH, (1989) Likelihood ratio tests for model selection and non-nested hypotheses. Econometrica 57: 307-33.
17. Zhang W, Samelson LE, (2000) The role of membrane-associated adaptors in T cell receptor signalling. Semin Immunol 12: 35-41.
18. Bruyns E, Marie-Cardine A, Kirchgessner H, Sagolla K, Shevchenko A, et al. (1998) T cell receptor (TCR) interacting molecule (TRIM), a novel disulfide-linked dimer associated with the TCR-CD3-zeta complex, recruits intracellular signaling proteins to the plasma membrane. J Exp Med 188: 561-575.
19. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, et al. (2008) Pten and p53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma. Cold Spring Harb Symp Quant Biol 73: 427-437.
20. Akervall J, Bockmuhl U, Petersen I, Yang K, Carey TE, et al. (2003) The gene ratios c-MYC:cyclin-dependent kinase (CDK)N2A and CCND1:CDKN2A correlate with poor prognosis in squamous cell carcinoma of the head and neck. Clin Cancer Res 9: 1750-1755.
21. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, et al. (2000) Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14: 391-396.
22. Song MS, Carracedo A, Salmena L, Song SJ, Egia A, et al. (2011) Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell 144: 187-199.
23. Getz G, Hoing H, Mesirov JP, Golub TR, Meyerson M, et al. (2007) Comment on "The consensus coding sequences of human breast and colorectal cancers". Science 317: 1500.
24. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, et al. (2007) Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA 104: 20007-20012.
25. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, et al. (2012) The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discovery 2: 401-404.
26. Szczurek E, Beerenwinkel N, (2014) Modeling Mutual Exclusivity of Cancer Mutations. In: Research in Computational Molecular Biology, Springer. pp pp. 307-308.